Marc Drezner

Biography

Dr. Marc Drezner obtained his MD from the University of Pittsburgh. He received his internal medicine and endocrinology training at Duke University Medical Center and remained on the faculty of the Duke University Medical School for twenty-five years. During his tenure at Duke University he was appointed Associate Professor of Medicine in 1981 and Professor of Medicine in 1987. He served as Director of the Endocrinology and Diabetes Training Grant from 1983 to 2000 and Director of the Stedman Nutrition Center from 1991 to 1997. Dr. Drezner joined the University of Wisconsin Hospital and Clinics (UWHC) in 2000, where he was appointed Professor of Medicine and served as Section Head of the Division of Endocrinology, Diabetes and Metabolism for 10 years. Dr. Drezner has also led the NIH-funded General Clinical Research Center. He currently serves as principal investigator of the NIH-funded Clinical and Translational Science Award (CTSA) at UW. He is also active at the federal level on major committees and projects associated with the $8 million CTSA grant that anchors the funding for ICTR. Dr. Drezner serves as Executive Director of the Institute for Clinical and Translational Research (ICTR) and Senior Associate Dean in the School of Medicine and Public Health (SMPH). Dr. Drezner is internationally known for his scientific work in bone and mineral metabolism and has made seminal contributions to our knowledge of several genetic diseases, including X-Linked Hypophosphatemic Rickets/Osteomalacia and Pseudohypoparathyroidism. In addition, he has brought new perspective to the management of Postmenopausal Osteoporosis, bringing attention to the psychosocial consequences of the disease. He is an experienced clinical and basic science investigator with more than 180 peer-reviewed original publications, more than 50 chapters and editorials, two books and numerous visiting professorships in the US and abroad. His pioneering work in the bone and mineral field led to the discovery of a new disease, Pseudohypopharathyroidism, Type 2; cloning the gene underlying the most common form of familial rickets; and defining and providing the name for a newly conceived hormone, phosphatonin. In the hypophosphatemic diseases of man, Dr. Drezner has helped set the research and clinical agendas worldwide and has contributed to defining new therapeutic approaches for these diseases. Dr. Drezner is on the Editorial Board of several journals and serves as the Editor Emeritus of the Journal of Bone and Mineral Research, the foremost clinical and basic science bone journal in the world today.

Research Interest

Pseudohypopharathyroidism, X-Linked Hypophosphatemic Rickets/Osteomalacia, Postmenopausal Osteoporosis,